Durability data presented at the European Society of Cardiology’s 2026 congress show CRISPR Therapeutics’ CTX310 — a single gene-editing infusion that silences a cholesterol-raising liver gene — sustained roughly 80 per cent reductions in the target protein and up to 84 per cent LDL cholesterol lowering a year after treatment, moving one-time gene-editing therapy for cardiovascular risk a step closer to real-world use.
A therapy designed to be given once and then left alone has now shown it can do exactly that for a full year. On 28 August 2026, at the European Society of Cardiology (ESC) Congress in a late-breaking presentation simultaneously published in the New England Journal of Medicine, CRISPR Therapeutics reported that a single infusion of its investigational gene-editing therapy CTX310 continued to suppress a cholesterol-raising liver protein and keep LDL cholesterol and triglycerides down twelve months after treatment, in the same small group of patients whose two-month results had already drawn attention earlier this year.
CTX310 uses CRISPR-Cas9 gene-editing machinery, delivered in lipid nanoparticles to the liver, to permanently switch off the gene for angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 normally blocks the breakdown of LDL cholesterol and triglycerides; people born with natural loss-of-function mutations in the gene — first identified in a long-lived population in Italy — have lifelong low cholesterol and triglycerides and markedly reduced rates of heart disease. CTX310 is designed to recreate that same protective mutation therapeutically, in adults with treatment-resistant lipid disorders, using a single intravenous dose rather than a mutation someone is born with.
What the one-year data show
In the Phase 1a trial’s highest-dose cohort — fifteen patients with severe, medication-resistant elevations in LDL cholesterol and triglycerides — circulating ANGPTL3 protein fell by a mean of 79 per cent from baseline, with a maximum reduction of 89 per cent, and remained suppressed at twelve months. Triglycerides fell by a mean of 48 per cent (maximum 78 per cent), and LDL cholesterol fell by a mean of 53 per cent (maximum 84 per cent) at the highest dose, essentially unchanged from the reductions reported after two months. No treatment-related serious adverse events occurred during the twelve-month follow-up, and there were no clinically significant (Grade 3 or higher) liver enzyme elevations beyond what had already been reported.
That durability is the finding’s real significance. A one-time treatment that produces a large initial drop in cardiovascular risk markers is useful; a one-time treatment whose effect persists unchanged for a year without additional dosing or monitoring burden is a materially different clinical proposition — it removes the adherence problem that undermines much of chronic cardiovascular pharmacotherapy. As CRISPR Therapeutics’ chief medical officer Naimish Patel put it in the company’s release accompanying the data, evidence that a single dose can produce lasting lipid lowering is central to the goal of developing genuinely one-time treatments for cardiometabolic disease, because for patients at high cardiovascular risk the biggest practical challenge is often not starting a therapy but staying on it for decades.
Where this sits in a broader field
CTX310 is one of several gene-editing programmes now targeting cardiovascular risk factors through liver-directed CRISPR editing, a field that has moved unusually quickly from mechanistic plausibility to human dosing over the past three to four years. Intellia Therapeutics’ nexiguran ziclumeran, targeting the TTR gene in transthyretin amyloid cardiomyopathy, has already progressed to a Phase 3 trial (MAGNITUDE) after a Phase 1 study showed roughly 90 per cent average reductions in serum transthyretin at twelve months, though that programme paused new patient enrolment in October 2025 for reasons unrelated to CTX310. Separately, Scribe Therapeutics has an epigenetic (non-cutting) silencing approach targeting PCSK9 — a different, more established cardiovascular target — expected to enter Phase 1 trials in 2026. CTX310 is now advancing into a Phase 1b trial, with US and international arms ongoing and a further data update expected in the second half of 2026; the company has separately indicated it is pursuing apolipoprotein(a) gene editing for elevated Lp(a), another inherited cardiovascular risk factor with no approved targeted therapy today.
Why it matters
Cardiovascular disease remains the leading cause of death worldwide, including in India, where rates of premature coronary artery disease and often severe, difficult-to-manage lipid abnormalities are well documented in the clinical literature and are frequently linked to genetic factors that respond poorly to standard statin therapy alone. A durable, single-dose therapy targeting a genetic driver of high LDL cholesterol and triglycerides — rather than a daily medication requiring lifelong adherence — would represent a genuinely different treatment paradigm for exactly the patient population that current lipid-lowering drugs serve worst: those with treatment-resistant disease.
The caveats are those appropriate to a fifteen-patient Phase 1a cohort with one year of follow-up: this is a small, early-stage safety and durability study, not a trial statistically powered to demonstrate reductions in heart attacks, strokes or cardiovascular death, and those outcome data — the actual clinical payoff of lower LDL and triglycerides — will take considerably larger and longer trials to establish. Long-term safety of permanent, irreversible gene editing in the liver, including any late-emerging off-target effects, also requires longer observation than a single year provides. But a genetically engineered one-time treatment holding its effect, unchanged, a full year after infusion is a meaningfully strong durability signal for a class of therapy still working to prove that CRISPR-based interventions can move from laboratory concept to a genuine alternative to lifelong pharmacotherapy.
– Srinayana Kavuri
Key facts
– CTX310: CRISPR-Cas9 gene-editing therapy silencing ANGPTL3 in the liver via lipid nanoparticle delivery, developed by CRISPR Therapeutics
– One-year data (highest dose, n=15): mean 79% reduction in ANGPTL3 protein, 53% mean LDL cholesterol reduction (max 84%), 48% mean triglyceride reduction (max 78%); no treatment-related serious adverse events
– Presented as a late-breaking trial at ESC Congress 2026 and simultaneously published in the New England Journal of Medicine, 28 August 2026
– Advancing to Phase 1b trial (US and international arms); further update expected second half of 2026
– Part of a wider field of liver-directed CRISPR cardiovascular therapies, including Intellia’s nexiguran ziclumeran (Phase 3, TTR-amyloid cardiomyopathy) and Scribe Therapeutics’ PCSK9 programme
